Beodeul Kang
Overview
Explore the profile of Beodeul Kang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cheon J, Jung S, Kim J, Kang B, Kim H, Chan L, et al.
Liver Int
. 2024 Apr;
44(8):1961-1970.
PMID: 38618972
Background And Aims: Anti-programmed death 1 (PD-1) monotherapy triggers various responses by each organ. In advanced hepatocellular carcinoma (HCC), while extrahepatic lesions demonstrate objective response rates (ORR) of 20%-40%, only...
12.
Lee J, Yoo I, Hong S, Kang B, Kim J, Kim Y, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612748
Visceral adiposity is known to be related to poor prognosis in patients with cholangiocarcinoma; however, the prognostic significance of the qualitative features of adipose tissue in cholangiocarcinoma has yet to...
13.
Sang Y, Lee C, Kim S, Lee B, Kang B, Kim C, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592150
The coronavirus disease 2019 (COVID-19) pandemic has proven challenging to the management of patients with cancer, particularly those receiving systemic therapy. This study aimed to evaluate the impact of COVID-19...
14.
Yoo S, Kang J, Kim H, Lee S, Hong M, Jung E, et al.
Sci Rep
. 2024 Mar;
14(1):6004.
PMID: 38472471
The prevalent use of opioids for pain management in patients with advanced cancer underscores the need for research on their neuropsychiatric impacts, particularly delirium. Therefore, we aimed to investigate the...
15.
Chon Y, Kim D, Kim M, Kim B, Kim S, Park J, et al.
Clin Mol Hepatol
. 2024 Mar;
30(3):345-359.
PMID: 38468561
Background/aims: Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of...
16.
Jung E, Yoo S, Lee S, Kang B, Kim Y
Cancer Res Treat
. 2024 Feb;
56(4):1277-1287.
PMID: 38419423
Purpose: Delirium is a common neurocognitive disorder in patients with advanced cancer and is associated with poor clinical outcomes. As a potentially reversible phenomenon, early recognition of delirium by identifying...
17.
Kim H, Jung S, Lim H, Ryoo B, Ryu M, Chuah S, et al.
Nat Med
. 2024 Feb;
30(3):699-707.
PMID: 38374347
Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients...
18.
Song Y, Yang H, Kang B, Cheon J, Kim I, Kim H, et al.
Liver Cancer
. 2024 Feb;
13(1):89-98.
PMID: 38344445
Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors,...
19.
Cheon J, Kim H, Kim H, Kim C, Kim I, Kang B, et al.
Ther Adv Med Oncol
. 2023 Sep;
15:17588359221148541.
PMID: 37705533
Background: Atezolizumab plus bevacizumab (Ate/Bev) demonstrated promising efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase III IMbrave150 trial. However, patients with Child-Pugh B HCC were...
20.
Kim Y, Yang H, Lee W, Cheon J, Sang Y, Kang B, et al.
J Cancer
. 2023 May;
14(6):935-942.
PMID: 37151396
Immune checkpoint inhibitor (ICI) became a standard treatment for advanced renal cell carcinoma (RCC). However, clinically valid biomarkers of therapeutic outcome are lacking. We investigated the role of interleukin-10 (IL-10)...